← Back to Home

RAS-targeted pancreatic cancer drug daraxonrasib wins FDA approval, with median survival of 13.2 months in trial

A randomized trial of 500 patients has secured a place for an oral RAS-targeted therapy in metastatic pancreatic cancer treatment. Improved survival offers a new option, but the scope of approval, trial population, and serious side effects must be understood together.

By SURL BioNews

For patients with metastatic pancreatic cancer whose disease continues to progress despite prior treatment, the significance of a new therapy lies in whether it can truly provide more time. Daraxonrasib, an oral drug developed by Revolution Medicines, extended overall survival in a randomized trial and received approval from the U.S. Food and Drug Administration (FDA) on August 26, 2026, bringing RAS-targeted treatment into clinical use.

The drug, marketed as Rasonque, is a RAS GTPase family inhibitor. It is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one systemic therapy or are not suitable for multidrug systemic therapy. This scope does not encompass all patients with pancreatic cancer and cannot be directly extended to operable or nonmetastatic disease.

The approval was based on the RASolute 302 trial: 500 patients whose disease had progressed after first-line systemic therapy were randomly assigned to receive daraxonrasib or standard chemotherapy selected by their physician. The trial had an open-label design, but progression-free survival was assessed by an independent central review blinded to treatment assignment, helping reduce the possibility that knowledge of treatment assignment could influence imaging assessments.

In the overall population, median overall survival was 13.2 months in the drug group and 6.7 months in the chemotherapy group; median progression-free survival was 7.2 and 3.6 months, respectively. The FDA said statistically significant improvements in efficacy were observed in both the overall population and the population with RAS G12 mutations. STAT also identified the survival results as central to the significance of this approval. However, medians reflect group results and should not be interpreted as meaning that every patient will gain the same amount of survival time.

Another distinction requiring attention is that the scope of approval and the direct trial evidence do not fully overlap. The indication listed by the FDA includes patients who are not suitable for multidrug systemic therapy, but the pivotal trial described in the approval announcement enrolled patients whose disease had progressed after first-line treatment. The overall figures in the announcement alone therefore cannot establish that all eligible patients will receive the same magnitude of benefit.

Oral administration also comes with safety risks. The FDA-recommended dose is 300 milligrams once daily, and the prescribing information includes warnings for skin and soft tissue toxicity, stomatitis, diarrhea, gastrointestinal perforation, and interstitial lung disease or pneumonitis. The announcement did not provide the incidence of each serious adverse event, leaving insufficient information for a full comparison of its safety burden with that of chemotherapy.

Background

Revolution Medicines is also advancing another drug, zoldonrasib, which targets RAS G12D, exploring its use with chemotherapy as a first-line treatment for pancreatic cancer. That research involves a different drug at a different treatment stage and should not be conflated with this approval of daraxonrasib. This development provides clinical evidence that RAS-targeted treatment can improve survival; whether earlier use or combinations with other therapies can further expand the benefits remains a question for the respective trials to answer.

References

  1. STAT
  2. FDA